On Target Laboratories’ fluorescence imaging technology is being developed to illuminate cancer during surgery, potentially enabling surgeons to see and remove more diseased tissue.
Surgeons step into the OR with a variety of pre-operative inputs that help locate tumors and suspicious lesions — but finding small lesions can still be challenging.
By targeting and illuminating cancerous tissue during a procedure, On Target’s technology has the potential to give skilled surgeons the added benefit of intraoperative sight. This added visibility may increase the likelihood of a more complete surgical resection. Complete resections are associated with reduced re-operations or adjuvant treatments1, and for patients could translate into improved outcomes.
On Target’s technology gives surgeons intraoperative visibility of cancerous tissue, potentially increasing the chance for a complete surgical resection.
1. Riquet, Mark, et al. Microscopic Residual Disease After Resection for Lung Cancer: A Multifaceted but Poor Factor of Prognosis. Ann Thorac Surg. 2010;89: 870-6. doi:10.1016/j.athoracsur.2009.12.037.
Brand Strategy By
Assembly
Developed By
Alchemy + Aim